A Phase I Clinical Trial of BAT5906 Injection in Patients With Wet Age-related Macular Degeneration
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Age - Related Macular Degeneration
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 50 years and 80 years
- Gender
- Both males and females
Description
The primary objective: To evaluate the safety and Pharmacokinetics of BAT5906 (single-dose Ophthalmic Intracireal Iinjection) in patients wAMD , when the injection dosage escalates. The Secondary objective: To evaluate the immunogenicity profile of BAT5906; To evaluate the pharmacodynamics and thera...
The primary objective: To evaluate the safety and Pharmacokinetics of BAT5906 (single-dose Ophthalmic Intracireal Iinjection) in patients wAMD , when the injection dosage escalates. The Secondary objective: To evaluate the immunogenicity profile of BAT5906; To evaluate the pharmacodynamics and therapeutic efficacy profile of BAT5906.
Tracking Information
- NCT #
- NCT04151212
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Youxin Chen Peking Union Medical College
Get Well Soon